1) Ongoing series of arrests amidst deteriorating armed conflict in Dekai: Four Papuan girls arbitrarily detained including three minors
Pattern of repeated arbitrary arrests in Dekai
Human rights analysis
All patinets and medical staff left the Yahukimo Regional Public Regional Hospital (RSUD), 18 February 2026
Security forces increased patrols in Dekai and deployed additional personnel to secure health facilities and government offices in Dekai, 18 February 2026
Location: Dekai, Yahukimo regency, Highland Papua, Indonesia (-4.8638158, 139.4837298) Kilo 5
Total number of victims: 4
| # | Number of Victims | Name, Details | Gender | Age | Group Affiliation | Violations |
| 1. | 1 | Mira Silip | female | 19 | Indigenous Peoples | arbitrary detention |
| 2. | 1 | Emeri Kobak | female | 12 | Indigenous Peoples | arbitrary detention |
| 3. | 1 | Neti Silip | female | 13 | Indigenous Peoples | arbitrary detention |
| 4. | 1 | Silfa Kobak | female | 7 | Indigenous Peoples | arbitrary detention |
Perpetrator: Indonesian Security Forces
Issues: indigenous peoples, women and children
Malaria remains a serious health threat in Greater Papua, where many communities live in areas with year-round transmission. Each year, Greater Papua’s six provinces account for over 90% of malaria cases in Indonesia. The main medicines used to cure malaria, known as artemisinin-based combination therapies (ACTs), have saved many lives. However, malaria parasites are gradually becoming less sensitive to these medicines in some parts of the world. If this happens in Indonesia, the medicines may lose their effectiveness, endangering patients and accelerating disease spread.
Indonesia has previously witnessed significant shifts in malaria drug performance. Before 2004, chloroquine and sulphadoxine-pyrimethamine were the standard treatments. As antimicrobial resistance increased, these medicines failed to cure sufficient numbers of patients, prompting a transition to ACTs. In 2010, authorities adopted dihydroartemisinin-piperaquine (DHA-PPQ) as the first-line treatment. Regular monitoring ensures that national malaria treatment policy remains aligned with changes in parasite resistance.
From August 2024 to October 2025, the Ministry of Health, with support from the World Health Organization (WHO), provincial and district health offices, Hasanuddin University, and the National Research and Innovation Agency, conducted a therapeutic efficacy study in Keerom and Kepulauan Yapen districts, Papua. Following WHO protocols, researchers examined more than 700 malaria patients. The study assessed three medicines: DHA-PPQ, artesunate-pyronaridine (ASPY) and artemether-lumefantrine (AL).
The findings were encouraging. No delayed parasite clearance occurred, meaning the medicines eliminated malaria parasites from the blood within expected timeframes. No serious adverse events were reported, and all three medicines maintained high effectiveness, with only a small number of patients experiencing persisting malaria symptoms. Scientists are now examining these few cases using molecular methods to determine whether they represent genuine resistance or new infections.
For Indonesia, these findings provide strong local evidence to confirm the continued use of DHA-PPQ as first-line treatment. They also guide the selection of effective second-line options such as ASPY and AL if treatment failure increases in specific areas. For communities in Papua, this means treatments that remain effective, faster recovery, fewer complications and better protection against ongoing transmission.
Work continues to analyse resistance markers in malaria parasites and distinguish reinfection from genuine treatment failure. Sentinel sites in Papua and other priority provinces will remain essential for tracking changes in drug performance. Through this collaboration, WHO and national partners are strengthening laboratory capacity and clinical monitoring, enabling Indonesia to respond swiftly should resistance patterns change.
This activity is supported by The Global Fund.
TEMPO.CO, Jakarta - The American mining company, Freeport-McMoRan, has announced an agreement with the Indonesian Government to extend the operating rights of PT Freeport Indonesia (PTFI) in Papua until 2041. The agreement is outlined in a Memorandum of Understanding that governs the continuation of operations in the Grasberg Mineral District.
Under the agreement, the Special Mining Business Permit (IUPK) of PTFI will be amended to extend the operating rights until the life of the mine reserves. This change strengthens the Grasberg mine's legal certainty for the next two decades.
he Chair of Freeport's Board of Directors, Richard C. Adkerson, expressed his appreciation for the long-term partnership with the Indonesian Government. He stated that the Grasberg mining operation in Papua has provided significant benefits to all stakeholders over the past six decades.
"And this extension will open opportunities to continue creating significant value for all parties in one of the largest copper and gold reserves in the world," said Adkerson, as quoted from the written statement on Thursday, February 19, 2026.
However, this extension is still awaiting the issuance of the revised IUPK by the Indonesian Government. PTFI stated that it will soon complete the application process for the permit extension in accordance with the provisions agreed upon in the MoU.
In addition to licensing aspects, Freeport also stated additional commitments to the Papua community. The company will provide additional social support, including funding for the construction of a new hospital and two medical education facilities. In the upstream sector, PTFI plans to increase exploration budgets and expedite studies to discover new resources and long-term expansion opportunities.
On the downstream side, the company emphasized its priority to prioritize refining and selling products domestically, including processed copper, precious metals, sulfuric acid, and other derivative products. According to market mechanisms, Freeport also sees the opportunity to expand the marketing of refined copper to the United States if demand increases in that country.
The agreement also regulates changes in the share ownership structure. In 2041, Freeport will transfer an additional 12 percent of PTFI shares to the government at no cost. This transfer comes with the provision of proportional investment cost reimbursement, which will continue to provide benefits based on book value after 2041. Freeport will hold 48.76 percent of PTFI shares until 2041, after which that portion will decrease to around 37 percent.
The company ensures that the governance structure, operations, and provisions in the current shareholder agreements and IUPK will be maintained throughout the life of the mining reserves.